CaseVu
Q1-2020 Reported Revenues Increase 77% Over Q4-2019 To $1.2M
Precipio Pathology Sales Performance Metrics Demonstrate Growth in Customer Acquisition, Retention, and Total Case Volume [...]
May
Precipio Announces Q1-2020 Corporate Update Call For Shareholders
Conference Call to be held on Tuesday, May 19th, 2020 at 5:00 PM EST NEW [...]
May
Precipio Launches New HemeScreen™ Reagent Rental Program
Oncology Practices Improve Patient care and Increase Revenue & Profit NEW HAVEN, CT, (April 6th, [...]
Apr
Company Update During The COVID-19 Era
Letter to the Shareholders from the CEO NEW HAVEN, CT, (March 20th, 2020) – Specialty diagnostics [...]
Mar
Precipio Completes The Transaction With Poplar Healthcare’s Oncometrix Hematopathology Division
Customer base and sales team transition to Precipio, Doubling Revenues NEW HAVEN, CT, (March 16th, [...]
Mar
Precipio Achieves Impressive Initial Results Of Artificial Intelligence Decision-Support Tool
Groundbreaking clinical and economic impact to be generated NEW HAVEN, CT, (February 26th, 2020) – Specialty [...]
Feb
Precipio In Advanced Discussions With Poplar Healthcare Towards A Multi-Faceted Strategic Partnership
NEW HAVEN, CT, (February 18th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it [...]
Feb
Precipio Provides Clarification To Amendment No.1 To Form S-1 Filing
NEW HAVEN, CT, (January 28th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]
Jan
Precipio Provides Clarification To Recent S-1 Filing
NEW HAVEN, CT, (January 15th, 2020) – The management team of specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), [...]
Jan
Precipio Announces Shareholder Update Call To Kick Off 2020
NEW HAVEN, CT, (January 13th, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, [...]
Jan